Fei Wang1, Sahara J Cathcart2, Dominick J DiMaio2, Nan Zhao1, Jie Chen2, Michele R Aizenberg3, Nicole A Shonka4, Chi Lin1, Chi Zhang5. 1. Department of Radiation Oncology, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198-7521, USA. 2. Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA. 3. Department of Neurosurgery, University of Nebraska Medical Center, Omaha, NE, USA. 4. Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA. 5. Department of Radiation Oncology, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198-7521, USA. chi.zhang@unmc.edu.
Abstract
PURPOSE: Glioblastoma (GBM) is the most lethal primary brain tumor in adult patients. The disease progression, response to chemotherapy and radiotherapy at initial diagnosis, and prognosis are profoundly associated with the tumor microenvironment, especially the features of tumor-infiltrating immune cells (TII). Recurrent GBM is even more challenging to manage. Differences in the immune environment between newly diagnosed and recurrent GBM and an association with tumor prognosis are not well defined. METHODS: To address this knowledge gap, we analyzed the clinical data and tissue specimens from 24 GBM patients (13 at initial diagnosis and 11 at recurrence). The expression levels of multiple immunobiological markers in patients' GBM at initial diagnosis versus at recurrence were compared, including five patients with both specimens available (paired). The distribution patterns of TII were evaluated in both the intratumoral and perivascular regions. RESULTS: We found that tumors from recurrent GBM have significantly more tumor-infiltrating lymphocytes (TILs) and macrophages and higher PD-L1 and PD-1 expression than tumors at primary diagnosis and benign brain specimens from epilepsy surgery. The pattern changes of the TILs and macrophages of the five paired specimens were consistent with the unpaired patients, while the CD8 to CD4 ratio remained constant from diagnosis to recurrence in the paired tissues. The levels of TILs, macrophages, PD-1 or PD-L1+ cells at initial diagnosis did not correlate with OS. TILs, macrophages, and PD-1+ cells were increased in recurrent tumors both in intratumoral and perivascular areas, with higher distribution levels in intratumoral than perivascular regions. Higher CD4 or CD8 infiltration at recurrence was associated with a worse prognosis, respectively. CONCLUSIONS: Our study elucidated that TIL and TAM tend to accumulate in perivascular region and are more abundant in recurrent GBM than newly diagnosed GBM.
PURPOSE: Glioblastoma (GBM) is the most lethal primary brain tumor in adult patients. The disease progression, response to chemotherapy and radiotherapy at initial diagnosis, and prognosis are profoundly associated with the tumor microenvironment, especially the features of tumor-infiltrating immune cells (TII). Recurrent GBM is even more challenging to manage. Differences in the immune environment between newly diagnosed and recurrent GBM and an association with tumor prognosis are not well defined. METHODS: To address this knowledge gap, we analyzed the clinical data and tissue specimens from 24 GBM patients (13 at initial diagnosis and 11 at recurrence). The expression levels of multiple immunobiological markers in patients' GBM at initial diagnosis versus at recurrence were compared, including five patients with both specimens available (paired). The distribution patterns of TII were evaluated in both the intratumoral and perivascular regions. RESULTS: We found that tumors from recurrent GBM have significantly more tumor-infiltrating lymphocytes (TILs) and macrophages and higher PD-L1 and PD-1 expression than tumors at primary diagnosis and benign brain specimens from epilepsy surgery. The pattern changes of the TILs and macrophages of the five paired specimens were consistent with the unpaired patients, while the CD8 to CD4 ratio remained constant from diagnosis to recurrence in the paired tissues. The levels of TILs, macrophages, PD-1 or PD-L1+ cells at initial diagnosis did not correlate with OS. TILs, macrophages, and PD-1+ cells were increased in recurrent tumors both in intratumoral and perivascular areas, with higher distribution levels in intratumoral than perivascular regions. Higher CD4 or CD8 infiltration at recurrence was associated with a worse prognosis, respectively. CONCLUSIONS: Our study elucidated that TIL and TAM tend to accumulate in perivascular region and are more abundant in recurrent GBM than newly diagnosed GBM.
Authors: Beth K Neilsen; Richard Sleightholm; Rodney McComb; Shakti H Ramkissoon; Jeffrey S Ross; Robert J Corona; Vincent A Miller; Matthew Cooke; Michele R Aizenberg Journal: J Neurooncol Date: 2018-12-09 Impact factor: 4.130
Authors: Malte Mohme; Simon Schliffke; Cecile L Maire; Alessandra Rünger; Laura Glau; Klaus C Mende; Jakob Matschke; Christina Gehbauer; Nuray Akyüz; Svenja Zapf; Mareike Holz; Miriam Schaper; Tobias Martens; Nils O Schmidt; Sven Peine; Manfred Westphal; Mascha Binder; Eva Tolosa; Katrin Lamszus Journal: Clin Cancer Res Date: 2018-02-14 Impact factor: 12.531
Authors: Lina Marenco-Hillembrand; Olindi Wijesekera; Paola Suarez-Meade; David Mampre; Christina Jackson; Jennifer Peterson; Daniel Trifiletti; Julie Hammack; Kyle Ortiz; Elizabeth Lesser; Matthew Spiegel; Calder Prevatt; Maria Hawayek; Alfredo Quinones-Hinojosa; Kaisorn L Chaichana Journal: J Neurooncol Date: 2020-03-09 Impact factor: 4.130
Authors: Allen Waziri; Brendan Killory; Alfred T Ogden; Peter Canoll; Richard C E Anderson; Sally C Kent; David E Anderson; Jeffrey N Bruce Journal: J Immunol Date: 2008-06-01 Impact factor: 5.422
Authors: Samir Devalaraja; Tsun Ki Jerrick To; Ian W Folkert; Ramakrishnan Natesan; Md Zahidul Alam; Minghong Li; Yuma Tada; Konstantin Budagyan; Mai T Dang; Li Zhai; Graham P Lobel; Gabrielle E Ciotti; T S Karin Eisinger-Mathason; Irfan A Asangani; Kristy Weber; M Celeste Simon; Malay Haldar Journal: Cell Date: 2020-03-12 Impact factor: 66.850